boron and Atherosclerosis

Senescence-associated diseases have severely diminished the quality of life and health of patients. However, a sensitive assay of these diseases remains limited due to a lack of straightforward methods. Considering that senescence-associated β-galactosidase (SA-β-Gal) is overexpressed in senescent cells, the detection of SA-β-Gal in senescent cells and tissues might be a feasible strategy for the early diagnosis of SA diseases. In this study, a β-galactosidase-activatable nanoprobe

Topics: Animals; Atherosclerosis; beta-Galactosidase; Boron; Cellular Senescence; Fluorescent Dyes; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Nanoparticles; Porphobilinogen; Rats; Rats, Sprague-Dawley

We describe our solution for removal of the low-density lipoprotein (LDL) depot contained in proteins and lipids as a 'druggable' target for atherosclerotic cardiovascular diseases by neutron dynamic therapy (NDT), which we developed using boron tracedrugs for NDT against bovine serum albumin as a model protein. Thus, we examined, among our developed boron tracedrugs, a boron-containing curcuminoid derivative UTX-51, to destroy freshly isolated human LDL dynamically under irradiated thermal neutron to obtain a decreased intensity of band of LDL treated with UTX-51 and thermal neutron irradiation in their SDS-PAGE and electrophoresis analysis. These results suggest that UTX-51 might be a novel candidate of 'beyond chemical' therapeutic agents for atherosclerotic cardiovascular disease.

Topics: Animals; Atherosclerosis; Boron; Boron Neutron Capture Therapy; Cardiovascular Diseases; Cattle; Humans; Lipoproteins, LDL; Neutrons; Serum Albumin, Bovine